{'fraction_non_alphanumeric': 0.022222222222222223, 'fraction_numerical': 0.02139917695473251, 'mean_word_length': 4.818181818181818, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India.

Lymphatic filariasis (LF) is an important public health problem in India not only due to morbid condition but also due to social stigma, sexual incapacitation and considerable economic loss. About 64% of global population who are at risk of LF infection are living in southeast Asia region. It is estimated that 554.2 million people are at risk of LF infection in 243 districts across 20 states and union territories in India1. National Health Policy 2002 aims at elimination of transmission and prevention of disability due to LF by the year 2015. The most practical and feasible method of controlling LF is rapid reduction of microfilarial load in the community by annual mass drug administration (MDA) of a single dose of Di-ethylcarbamazine (DEC). The World Health Organization (WHO) has recently called on member of states to identify the global elimination of LF as a public health priority2. The global strategy to interrupt transmission of LF is a single-dose, two-drug regimen to be used by communities at risk with the goal of reaching 80% coverage for 4–6 years3.